急性缺血性卒中溶栓前逆转维生素K拮抗剂治疗
这项先导研究前瞻性纳入26例正在使用维生素K拮抗剂且INR>1.7的急性缺血性卒中患者,在静脉输注4因子凝血酶原复合物浓缩物和维生素K后立即进行静脉溶栓。逆转后5分钟INR从2.3±0.6降至1.3±0.2,前3天无症状性颅内出血或血栓事件,3个月时61.5%患者改良Rankin量表评分≤2。作者认为该策略可能可行且安全,但需随机对照试验证实。
要点
- 26例VKA相关INR>1.7的急性缺血性卒中患者,逆转后立即静脉溶栓。
- 逆转后5分钟INR从2.3±0.6降至1.3±0.2。
- 前3天无症状性颅内出血或血栓事件,3个月61.5%患者mRS≤2。
核心结论
- 在INR>1.7的维生素K拮抗剂治疗急性缺血性卒中患者中,静脉溶栓前使用4因子凝血酶原复合物浓缩物弹丸输注和维生素K的逆转策略可能可行且安全。
- 作者认为需要设计良好的随机对照试验来证实这些初步发现。
研究设计与样本
- 前瞻性先导研究,连续纳入除维生素K拮抗剂使用和INR>1.7外其他方面符合静脉溶栓条件的急性缺血性卒中患者,共26例。
- 干预为输注4因子凝血酶原复合物浓缩物和维生素K后立即进行静脉溶栓,在24小时进行临床和脑影像学安全性与有效性评估。
主要发现
- 26例患者年龄77.8±12.8岁,心房颤动占84.6%,初始美国国立卫生研究院卒中量表评分11.6±5.6。
- INR初始为2.3±0.6,逆转后5分钟为1.3±0.2。
- 前3天无患者发生症状性颅内出血或血栓事件。
- 1例患者发生需要输血的重大系统性痔出血。
- 3个月时61.5%的患者独立(改良Rankin量表评分≤2)。
局限性
- 作者认为需要设计良好的随机对照试验来证实这些初步发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Acute ischemic strokes under vitamin K antagonist (VKA) treatment are not uncommon, but intravenous thrombolysis (IVT) is not recommended for international normalized ratio (INR) >1.7 because of the excess bleeding risk. However, VKA-induced anticoagulation can be easily reversed by IV infusions of 4-factor prothrombin complex concentrate bolus and vitamin K. Our pilot study aimed to determine whether IVT immediately after anticoagulation reversal could be feasible and safe in acute ischemic stroke patients under VKA with INR >1.7. Methods- Consecutive acute ischemic stroke patients, otherwise eligible for IVT except for VKA intake and INR >1.7, were given IVT after infusing 4-factor prothrombin complex concentrate and vitamin K. Safety and efficacy were assessed clinically and by cerebral imaging at 24 hours. Results- Twenty-six patients (age, 77.8±12.8 years; atrial fibrillation, 84.6%; initial National Institutes of Health Stroke Scale, 11.6±5.6) were prospectively included. INR values were 2.3±0.6 initially and 1.3±0.2, 5 minutes postreversal. No symptomatic intracranial hemorrhage or thrombotic events occurred during the first 3 days. One patient developed major systemic hemorrhoidal bleeding that required blood transfusion; 61.5% of the patients were independent (modified Rankin Scale score of ≤2) at 3 months. Conclusions- A reversal strategy of 4-factor prothrombin complex concentrate bolus and vitamin K before IVT could be feasible and safe in acute ischemic stroke patients under VKA with INR >1.7. Well-designed, randomized controlled trials are warranted to confirm these preliminary findings.
引用
- Chausson N, Soumah D, Aghasaryan M, et al. Reversal of Vitamin K Antagonist Therapy Before Thrombolysis for Acute Ischemic Stroke. Stroke. 2018. PMID: 30355096. doi:10.1161/STROKEAHA.118.020890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。